This module is CPD certified, offering a certificate upon completion.
You will need to be signed in to MSD Connect to download the certificate.
Optimising Patient Care: hear from your peers
Optimising Patient Care: hear from your peers
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
This series of bite sized peer-to-peer videos by experienced clinical nurse specialists, specialist registrars and oncologists has been created to share their knowledge and experience of the day-to-day management of patients with mNSCLC treated with KEYTRUDA® (pembrolizumab) plus chemotherapy.
This module is part of a series of modules looking to share HCPs’ experiences across a range of topics. In this module we’ll start with how patients go into combination treatment and explore the proposed mode of action for KEYTRUDA. We’ll then look at the types of immune related adverse events which patients on KEYTRUDA plus chemotherapy may experience and how they may be managed. Finally, we’ll hear from a nurse about supporting patients as they complete their treatment and transition off KEYTRUDA.
- KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations
- KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations
- KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous non-small cell lung carcinoma in adults
- KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA
- Module Introduction
- PD-L1, KEYTRUDA and patients
- Explaining Mode of Action
- Autoimmune disease and KEYTRUDA
- Overview of immune related adverse events
- Extending chemotherapy guidance
- Immuno versus chemo related adverse events
- Coming off treatment at 2 years
- Module summary
An introduction to module one of the Peer-to-Peer KEYLearning video series
Length: 00:59 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
The role of PD-L1 testing in selecting patients for immunotherapy plus chemotherapy
Length: 08:46 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Explaining the mode of action of KEYTRUDA (pembrolizumab) plus chemotherapy combination therapy to patients
Length: 08:31 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Using KEYTRUDA (pembrolizumab) plus chemotherapy in patients with pre-existing autoimmune disease
Length: 03:42 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Extending guidance for managing chemotherapy-related adverse events to include immune-related adverse events
Length: 07:20 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Supporting patients through the transition at the end of their KEYTRUDA (pembrolizumab) plus chemotherapy treatment
Length: 06:45 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
A Summary of module one of the Peer-to-Peer KEYLearning video series
Length: 01:04 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Reference
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
